Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
4.480
-0.210 (-4.48%)
At close: Feb 21, 2025, 4:00 PM
4.840
+0.360 (8.04%)
After-hours: Feb 21, 2025, 7:07 PM EST
Traws Pharma Revenue
Traws Pharma had revenue of $57.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $226.00K. In the year 2023, Traws Pharma had annual revenue of $226.00K.
Revenue (ttm)
$226.00K
Revenue Growth
n/a
P/S Ratio
19.68
Revenue / Employee
$12,556
Employees
18
Market Cap
16.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
TRAW News
- 4 weeks ago - Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu - PRNewsWire
- 6 weeks ago - Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program - PRNewsWire
- 7 weeks ago - Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval - PRNewsWire
- 2 months ago - Traws Pharma stock soars 200% on encouraging bird flu drug data - Invezz
- 2 months ago - Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu - PRNewsWire
- 3 months ago - Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results - GlobeNewsWire
- 4 months ago - Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - GlobeNewsWire
- 5 months ago - Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor - GlobeNewsWire